title: Recent advances in the secondary prevention of coronary heart disease.
abstract: Current practice guidelines provide recommendations for the secondary prevention of coronary heart disease. Following the publication of clinical trials in recent years, this review will highlight some controversial issues: the role of angiotensin and aldosterone antagonists after acute myocardial infarction; the effects of angiotensin-converting enzyme inhibitors in patients with stable coronary heart disease and preserved left ventricular ejection fraction; high-intensity lowering of low-density lipoprotein cholesterol; use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors in the elderly; and the targeting of high-density lipoprotein cholesterol with niacin.
authors.affiliation: Wingate University School of Pharmacy, Campus Box 3087, Wingate, NC 28174 0157, USA. aveverka@wingate.edu.
authors.forename: Angie
authors.initials: A
authors.lastname: Veverka
authors.forename: Jamie L
authors.initials: JL
authors.lastname: Jolly
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy / Q000401:mortality* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012084:Renin-Angiotensin System / Q000187:drug effects; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000924:Anticholesteremic Agents